Skip Navigation
Home
Browse Guidelines
Expert Commentaries
Guideline Syntheses
Guideline Matrix
Guideline Resources
Compare Guidelines
Frequently Asked Questions
Submit Guidelines
About
myNGC
< Back

'treatment failure'
Run an advanced search on this term

Search within:  

Sort results by:      



Filter results by:

1-9 of 9  
 
2.  
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 1998 Dec 1 (revised 2013 Feb 12). NGC:009618
Centers for Disease Control and Prevention - Federal Government Agency [U.S.]; Department of Health and Human Services (U.S.) - Federal Government Agency [U.S.]. View all guidelines by the developer(s)
3.  
Guidelines for the use of antiretroviral agents in pediatric HIV infection. 1999 Apr (revised 2012 Nov 5). [NGC Update Pending] NGC:009458
Centers for Disease Control and Prevention - Federal Government Agency [U.S.]; Department of Health and Human Services (U.S.) - Federal Government Agency [U.S.]. View all guidelines by the developer(s)
4.  
Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 1998 Jan 30 (revised 2012 Jul 31). [NGC Update Pending] NGC:009280
Centers for Disease Control and Prevention - Federal Government Agency [U.S.]; Department of Health and Human Services (U.S.) - Federal Government Agency [U.S.]; Public Health Service (U.S.) - Federal Government Agency [U.S.]. View all guidelines by the developer(s)
5.  
UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (2011). 2006 Feb (revised 2011 Dec). NGC:008902
British Association for Sexual Health and HIV - Medical Specialty Society. View all guidelines by the developer(s)
6.  
New antiretroviral drugs: maraviroc, raltegravir, etravirine, and rilpivirine. 2008 Apr (revised 2011 Nov). NGC:008821
New York State Department of Health - State/Local Government Agency [U.S.]. View all guidelines by the developer(s)
7.  
8.  
9.  
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. 2007 Aug (revised 2010 Aug). NGC:008062
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
1-9 of 9